loader from loading.io

In the News.. Medtronic safety alert, Omnipod 5 in Europe, T1D Index launched and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Release Date: 09/23/2022

When your sibling has T1D: Stacey's daughter Lea shares her story show art When your sibling has T1D: Stacey's daughter Lea shares her story

Diabetes Connections with Stacey Simms Type 1 Diabetes

Stacey talks a lot about her son with type 1 but, as many of you know, she also has a daughter who doesn’t have diabetes. What’s it like to grow up with a sibling who gets more attention for something you can’t do anything about? Lea was five when her little brother was diagnosed – she’s now 21 and she has a lot to say. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible!

info_outline
In the News... Teplizumab approved, Twitter mess for Lilly, Medtronic 7-day infusion set launches, and more! show art In the News... Teplizumab approved, Twitter mess for Lilly, Medtronic 7-day infusion set launches, and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It’s in the News.. the top diabetes stories of the past seven days. This week, the first drug to prevent T1D for any length of time is approved, Eli Lilly takes a financial hit from a Twitter impersonation stunt, Medtronic's 7-day pump infusion set is ready for consumers, Dexcom's G7 gets great reviews from older folks and educators for ease of use, a new study about light at night and diabetes and more! Learn more about the T1D Exchange: Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible!   Hello and welcome...

info_outline
The Future of Long-Term CGM Systems with Senseonics CMO Dr. Fran Kaufman show art The Future of Long-Term CGM Systems with Senseonics CMO Dr. Fran Kaufman

Diabetes Connections with Stacey Simms Type 1 Diabetes

Eversense is a CGM that goes under the skin and stays there for up to six months. The company that makes it has big plans to make that time period longer and to make the sensor even more accurate. Stacey talks to Senseonics Chief Medical Officer Dr. Francine Kaufman. They had a wide ranging conversation about everything from sensor length to interoperability and working with different pump systems as well as access and so much more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Episode Transcription Below (or...

info_outline
In the News.. Diabetes supply prices capped, New integrated insulin pen system, T1D diagnosis study and more! show art In the News.. Diabetes supply prices capped, New integrated insulin pen system, T1D diagnosis study and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It's in the News.. the top diabetes stories of the past seven days. This week, one state caps not just insulin prices, but diabetes supplies for some, Lilly is out with a new integrated pen system, new study look at DKA at diagnosis of type 1 and what that means for health issues later on, and more! Learn more about the T1D Exchange: Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible!   Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines...

info_outline
Tips, Tricks and Building a Community: Meet Tom From Type One Talks show art Tips, Tricks and Building a Community: Meet Tom From Type One Talks

Diabetes Connections with Stacey Simms Type 1 Diabetes

Type One Talks is a popular YouTube channel with videos that help manage all sort of technology and situations around diabetes. But its host and founder says he wasn’t always that interested a diabetes deep dive. It all changed with his first CGM. Tom was an accountant in his former life so he really does love numbers. We’ll talk about his diagnosis as a child in the former Czechoslovakia, how much everything has changed and why he started making videos about diabetes technology, basically experimenting on himself. This podcast is not intended as medical advice. If you have those kinds of...

info_outline
In the News... Researching T2D drugs for T1D, Medtronic 780G moves ahead, Diabetes Awareness Month stuff and more! show art In the News... Researching T2D drugs for T1D, Medtronic 780G moves ahead, Diabetes Awareness Month stuff and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It's in the News.. the top diabetes stories of the past seven days. This week: new research looks at off-label use of GLP and SGLT drugs for people with type 1, Medtronic gets 780G approval in Canada, finger prick early detection of type 1, and lots going on for Diabetes Awareness Month. Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to...

info_outline
What are your What are your "Rules of Engagement?"- Conversations around CGM

Diabetes Connections with Stacey Simms Type 1 Diabetes

When it comes to using a CGM, the first question you may ask is, "How quickly can I get one?!" But this week, you'll hear there are a few other questions you may want to ask in order to get the most out of continuous glucose monitoring. In this excerpt from "Still the World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes," Stacey lays out conversations to have BEFORE you decide whether and how to use a CGM. Thinking this out can make your child’s use of a CGM more effective and with less stress for you. It may even be helpful for adults considering...

info_outline
Building Community Through Storytelling: SixUntilMe's Kerri Sparling show art Building Community Through Storytelling: SixUntilMe's Kerri Sparling

Diabetes Connections with Stacey Simms Type 1 Diabetes

The author of Kerri Sparling, isn’t blogging any more, but she’s still looking for stories of connection and community built around conversation For 14 years Kerri wrote a daily blog about her experience with type 1. She put aside SixUntilMe in 2019. We’re going to talk about what she thinks about the online community these days and what’s next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the...

info_outline
In the News... insulin rationing, DIY tech studies, iLet pump research and more! show art In the News... insulin rationing, DIY tech studies, iLet pump research and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes...

info_outline
What happens at T1D teen retreats (and what adults can learn from them) show art What happens at T1D teen retreats (and what adults can learn from them)

Diabetes Connections with Stacey Simms Type 1 Diabetes

Who would volunteer to spend a weekend with a bunch of teens with type 1? A bunch of people who’ve been there! We’re talking about teen retreats – and what even adults can learn – about the power of connection. Patrick Mertes has lived with type 1 since he was a child. If that name sounds remember, he’s one of the climbers from the 50-in-50 project where he and a friend climbed the highest peak in all 50 states in 50 days a couple of years back. He also runs a fantastic family and teen retreat in North Carolina. This podcast is not intended as medical advice. If you have those kinds...

info_outline
 
More Episodes

It’s In the News! This week’s top diabetes headlines and stories include: cybersecurity risk cited for some Medtronic pumps, Omnipod 5 gets European approval, new data about the Freestyle Libre and avoiding hospitalizations, the new T1D Index and more!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
XX
potential cybersecurity risk for Medtronic MiniMed 600 Series Insulin Pump Systems. The FDA sent out an alert for multiple systems including the MiniMed 630 G and MiniMed 670G. They say this is a potential issue and that there have NOT been any reports of actually unauthorized access. Medtronic has issued an Urgent Medical Device Correction on their own website notifying users as well as providing recommended actions.
If unauthorized access occurs, the pump’s communication protocol could be compromised, which may cause the pump to deliver too much or too little insulin,” noted the FDA’s September 20 Cybersecurity alert.

On their website, Medtronic provides the Urgent Medical Device Correction, a list of model numbers impacted by the issue, and a multitude of frequently asked questions for device users. Within these resources, Medtronic notes the issue was identified through an internal review and, while the event meets the definition of a recall, users are not required to return their devices.

In a letter to users, which was signed by Chirag Tilara, vice president of Quality at Medtronic Diabetes, and Robert Vigersky, MD, chief medical officer at Medtronic Diabetes, the pair recommended all patients turn off the “Remote Bolus” feature on their pump if it is turned on, which is on by default. The letter also urged users to conduct any connection linking of devices in a nonpublic setting. Additional recommended precautions from Medtronic included keeping pump and connected system components within user control at all times, be attentive to pump notifications, alarms, and alerts, and immediately cancel any boluses you or your care partner did not initiate.

The FDA urged those with questions to reach out to Medtronic at 1-800-646-4633, option 1.
https://www.endocrinologynetwork.com/view/cybersecurity-risk-minimed-600-systems-alert-from-fda-medtronic
XX
Omnipod 5 gets the CE Mark, that’s European approval for individuals aged two years and older with type 1 diabetes. This comes as Insulet presents new studies at the European Association for the Study of Diabetes (EASD) meeting in Stockholm, Sweden.
https://www.businesswire.com/news/home/20220920005138/en/Insulet-Announces-CE-Mark-Approval-for-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System

XX
Abbott says the Freestyle Libre system can help reduce diabetes-related hospitalizations. Data from the Real-World Evidence of Freestyle Libre (RELIEF) were presented this week. The retrospective study of the French national health claims database shows that the 5,933 people with Type 2 diabetes who were following a basal-only regimen and using the FreeStyle Libre system had 67% fewer ADE-related hospitalizations one year after initiating the FreeStyle Libre treatment.
The data also show a 75% reduction in hospitalizations for diabetic ketoacidosis (DKA), a potentially life-threatening condition when glucose levels are too high for too long and ketone levels rise to dangerous levels in the blood, and a 44% reduction in admissions for severe hypoglycemia (low glucose levels).

Further, the study showed sustained reductions in hospitalizations over a two-year period of FreeStyle Libre system use, regardless of whether the patients were under the care of a diabetes specialist or a general healthcare practitioner.
https://www.mddionline.com/diabetes/can-abbotts-freestyle-libre-help-reduce-diabetes-related-hospitalizations
XX
A look at bone health and type 1 diabetes in teen girls. Small study herewith girls age 10-16.. found that the more sedentary had worse markers of bone health in imaging tests than girls without diabetes. When the groups had the same physical activity, no difference was seen regardless of diabetes. However, this is early research and further study is needed, the group cautions.

However, if further, rigorous studies confirm these findings, "physical activity is potentially a really effective means of improving bone quality in kids with type 1 diabetes."
https://www.medscape.com/viewarticle/981092
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
DRF, a global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.
The T1D Index and accompanying research has been published in The Lancet Diabetes & Endocrinology.

T1D is an autoimmune condition and one of the fastest-growing chronic health conditions, impacting nearly nine million people across the globe. Certain factors like family history can increase risk, but it is not caused by diet or lifestyle. T1D causes the pancreas to make very little insulin or none at all—this means the human body cannot convert food into energy, which can lead to long-term complications including damage to the kidneys, eyes, nerves, heart and even premature death. There is currently no cure for T1D.

"As a member of the T1D community, I know many are not as fortunate as I am to have the resources necessary to live a healthy and fulfilled life," Aaron Kowalski, Ph.D., JDRF CEO, said. "This is why I am so proud that significant progress has been made to understand T1D's global impact through the T1D Index. We are calling on government and public health decision makers throughout the world to utilize the tool to identify and implement interventions that can change the trajectory of T1D."

JDRF collaborated with key partners and experts around the world to develop the T1D Index—using the results from a global survey of more than 500 endocrinologists and 400 publications to simulate the state of T1D globally and at the country level.

The Index uniquely illuminates the human burden of T1D by highlighting "missing people," which is the number of people who would still be alive today if they had not died early due to complications from T1D, and "healthy years lost," which represents time lost to ill-health, disability or early death from living with T1D.

Simulations from the T1D Index suggest that globally, as of 2022, there are more than 3.86 million "missing people" and an average of 32 "healthy years lost" to T1D per person, if diagnosed at age 10.

T1D presents a profound human, emotional and financial burden for those who live with it—and prevalence is on the rise. Simulations from the T1D Index have led to the identification of four key interventions that could change the current trajectory for T1D and its impact on people around the world:

Timely diagnosis: enabling better education and training for medical professionals to accurately diagnose T1D. If the global population has access to timely diagnosis from 2023, 668,000 more people could be alive in 2040.
Insulin and strips: creating barrier-free access to insulin and blood glucose testing strips. If the global population has access to insulin and testing strips from 2023, and coaching to self-manage the condition, 1.98 million more people could be alive in 2040.
Pumps and CGMs: ensuring everyone living with T1D has access to technology that automates glucose monitoring and insulin delivery. 673,000 more people could be alive in 2040 if everyone with T1D has access to the technology available from 2023.
Prevention and cures: making the case for further investment and research in emerging prevention, treatments and cures. 890,000 more people could be alive in 2040 if we find cures.
Once interventions are identified on the global and country level, the T1D Index encourages users to take action by sharing the data and findings with their networks and local decision makers, and connecting with other T1D advocates in their communities.

Additionally, the T1D Index shines a light on important statistics about the burden of T1D globally, including:

Since 2000, T1D prevalence has increased at four times the rate of global population growth.
The expected number of people living with T1D in 2040 will be 17.43 million.
The number of "missing people" in the year 2040 is projected to be 6.85 million.
https://medicalxpress.com/news/2022-09-global-diabetes-index.htmlXX
XX